Intrajejunal levodopa infusion therapy for Parkinson’s disease: practical and pragmatic tips for successful maintenance of therapy

References

• LeWitt P, Fahn S. Levodopa therapy for Parkinson disease: a look backward and forward. Neurology. 2016;86(14 Suppl 1):3–12.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: 1325 dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464–474.
   PubMed Web of Science ®Google Scholar
• Jenner P. From the MPTP-treated primate to the treatment of motor complications in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(4):18–23.
   Google Scholar
• Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5(8):677–687.
   PubMed Web of Science ®Google Scholar
• Fernandez H, Standaert D, Hauser RA, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord. 2015;30(4):500–508.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Pirtosek Z, Pickut B, et al. Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: final long-term non-motor, quality of life and safety results from the GLORIA registry [abstract]. Mov Disord. 2016;31(suppl2). Available from: http://www.mdsabstracts.org/abstract/levodopa-carbidopa-intestinal-gel-in-routine-care-of-advanced-parkinsons-disease-patients-final-long-term-non-motor-quality-of-life-and-safety-results-from-the-gloria-registry/.
   Google Scholar
• Lang AE, Rodriguez RL, Boyd JT, et al. Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. Mov Disord. 2016;31(4):538–546.
   PubMed Web of Science ®Google Scholar
• Murato M, Mihara M, Hasegawa K, et al. Efficacy and safety of levodopa–carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson’s disease patient. NPJ Parkinsons Dis. 2016;2:16020.
   Google Scholar
• Antonini A, Mancini F, Canesi M, et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson’s disease. Neurodegener Dis. 2008;5(3–4):244–246.
   PubMed Web of Science ®Google Scholar
• Fasano A, Ricciardi L, Lena F, et al. Intrajejunal levodopa infusion in advanced Parkinson’s disease: long-term effects on motor and non-motor symptoms and impact on patient’s and caregiver’s quality of life. Eur Rev Med Pharmacol Sci. 2012;16(1):79–89.
   PubMed Web of Science ®Google Scholar
• Zibetti M, Merola A, Ricchi V, et al. Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study. J Neurol. 2013;260(1):105–114.
   PubMed Web of Science ®Google Scholar
• Sensi M, Preda F, Trevisani L, et al. Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients. J Neural Transm (Vienna). 2014;121(6):633–642.
   PubMed Web of Science ®Google Scholar
• Cáceres-Redondo MT, Carrillo F, Lama MJ, et al. Long-term levodopa/carbidopa intestinal gel in advanced Parkinson’s disease. J Neurol. 2014;261(3):561–569.
   PubMed Web of Science ®Google Scholar
• Wirdefeldt K, Odin P, Nyholm D. Levodopa–carbidopa intestinal gel in patients with Parkinson’s disease: a systematic review. CNS Drugs. 2016;30(5):381–404.
   PubMed Web of Science ®Google Scholar
• Schrader C, Böselt S, Wedemeyer J, et al. Asparagus and jejunal-through-PEG: an unhappy encounter in intrajejunal levodopa infusion therapy. Parkinsonism Relat Disord. 2011;17(1):67–69.
   PubMed Web of Science ®Google Scholar
• Merola A, Zibetti M, Rizzone MG, et al. Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients. Acta Neurol Scand. 2014;129(1):1–5.
   PubMed Web of Science ®Google Scholar
• Müller T, Van Laar T, Cornblath DR, et al. Peripheral neuropathy in Parkinson’s disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord. 2013;19(5):501–507. discussion 501.
   PubMed Web of Science ®Google Scholar
• Duodopa® Homepackage – Everyday. Version no: EN-C02-111027. Copyright © 2011 Abbott. All rights reserved. Produced by Animech AB 2011.
   Google Scholar
• Pedersen SW, Clausen J, Gregerslund MM. Practical guidance on how to handle levodopa/carbidopa intestinal gel therapy of advanced PD in a movement disorder clinic. The Open Neurol J. 2012;6:37–50.
   PubMedGoogle Scholar
• Odin P, Chaudhuri KR, Slevin JT, et al. National Steering Committees. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015;21(10):1133–1144.
   PubMed Web of Science ®Google Scholar
• Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicentre study of effects on nonmotor symptoms and quality of life. Mov Disord. 2009;24(10):1468–1474.
   PubMed Web of Science ®Google Scholar
• Reddy P, Martinez-Martin P, Rizos A, et al. Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. Clin Neuropharmacol. 2012;35(5):205–207.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015;30(4):510–516.
   PubMed Web of Science ®Google Scholar
• Reddy P, Martinez-Martin P, Brown RG, et al. Perceptions of symptoms and expectations of advanced therapy for Parkinson’s disease: preliminary report of a patient-reported outcome tool for advanced Parkinson’s disease (PRO-APD). Health Qual Life Outcomes. 2014;12:11.
   PubMed Web of Science ®Google Scholar
• Mancini F, Comi C, Oggioni GD, et al. Prevalence and features of peripheral neuropathy in Parkinson’s disease patients under different therapeutic regimens. Parkinsonism Relat Disord. 2014;20(1):27–31.
   PubMed Web of Science ®Google Scholar
• Bernstein RM. Reversible haemolytic anaemia after levodopa-carbidopa. Br Med J. 1979;1(6176):1461–1462.
   PubMed Web of Science ®Google Scholar